NEW DELHI:
Natco Pharma has applied for the country`s first compulsory licence to sell a
generic version of Bayer`s patented medicine, a development whose outcome is
expected to determine how global drug makers price their costly drugs in India.
In compulsory licensing, the government allows a generic firm to produce a
patented product without the consent of the patent owner. It is one of the
flexibilities on patent protection included in the WTO`s agreement on
intellectual property -TRIPS (trade-related aspects of intellectual property
rights) Agreement.
Natco stated in its application that the German company`s drug was unaffordable
for the average Indian, a person familiar with the development said. PH Kurien,
Controller General of Patents, said, "I understand they have filed the
application."
Bayer`s drug, Nexavar, which is used to treat liver and kidney cancer, costs
about 2.85 lakh for a month`s course. Natco said it can sell its generic
version, sorafenib tosylate, for just 8,900 for the same course.
Local drug firms and health activists are pushing for liberal use of compulsory
licensing, saying that innovator companies charge exorbitantly high prices for
their medicines. "A favourable decision for Natco will open the floodgates
and encourage other local firms to apply for compulsory licence for costly
patented medicines," a senior industry said.
YK Sapru, chairman and CEO of Cancer Patients Aid Association (CPAA), said
Natco`s application, if approved, would be a big relief to those who can`t
afford Nexavar. There are an estimated 25 lakh cancer patients in India. A
Natco spokesperson declined comment while Bayer did not respond to ET`s email.
In December,
Natco had sought a voluntary licence from Bayer for sorafenib tosylate that was
refused. Indian laws allow a firm to apply for a compulsory licence only after
the innovator company rejects the voluntary request.
Experts say the face-off is going to be a long drawn, as the loser will
invariably challenge the decision in court. There are at least two other
voluntary licence applications pending: Natco`s with a GSK-Pfizer joint venture
and Cipla`s with US-based Merck & Co.
For Bayer, this is not the first challenge for Nexavar. Cipla has already
launched its generic version without any permission and will have to pay
penalty if the court rules in favour of Bayer in a pending patent case.
Although compulsory licensing allows a generic firm to legally make and sell
the low-cost version, it has to pay some royalty, usually about 5% of sales.
MNCs strongly oppose the use of this provision because it breaks their
monopoly. They say such licensing is not a sustainable policy to address access
of medicines as these products account for much less than 1% of Indian drug
market.
Compulsory licensing provision has been used in countries such as Thailand,
Brazil and South Africa.
In all these nations, the provision was used for HIV medicines, according to a
commerce ministry discussion note on the use of such licences. India spends an
estimated $35 billion in healthcare cost. Unlike most other countries, where
such costs are state-funded or insured, 90% of Indians pay from their own
pocket.
Keywords: Natco / Pharma / India / compulsory
licence